Page 36 - 2021_09-Haematologica-web

R. Svanberg et al.
100.Gauthier J, Hirayama AV, Purushe J, et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020;135(19):1650-1660.
101. Long M, Williams E, Berard C, et al. Ibrutinib treatment in CLL patients improves T cell function and blinatumomab redirected cytotoxicity. Blood. 2019;134 (Suppl_1):1049.
102. Hanna BS, Yazdanparast H, Demerdash Y, et al. Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Eμ-TCL1 mice. Haematologica. 2021;106(4):968-977.
103.Younes A, Brody J, Carpio C, et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non- Hodgkin lymphoma or chronic lymphocytic
leukaemia: a phase 1/2a study. Lancet
Haematol. 2019;6(2):e67-e78.
104. Davis RJ, Moore EC, Clavijo PE, et al. Anti-
PD-L1 efficacy can be enhanced by inhibi- tion of myeloid-derived suppressor cells with a selective inhibitor of PI3Kδ/γ. Cancer Res. 2017;77(10):2607-2619.
(PF-06747143) in chronic lymphocytic
leukemia. J Hematol Oncol. 2017;10(1):1-16. 108. McWilliams EM, Lucas CR, Chen T, et al. Anti–BAFF-R antibody VAY-736 demon- strates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.
Blood Adv. 2019;3(3):447-460.
109. Chao MP, Alizadeh AA, Tang C, et al. Anti-
CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non- Hodgkin lymphoma. Cell. 2010;142(5):699-
105. Sam J, Colombetti S, Fauti T, et al. Combination of T-cell bispecific antibodies
with PD-L1 checkpoint inhibition elicits
superior anti-tumor activity. Front Oncol. 2020;10:1-15. 713.
106. Wierz M, Pierson S, Guyonnet L, et al. Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. Blood. 2018;131(14):1617-1621.
107. Kashyap MK, Amaya-Chanaga CI, Kumar D, et al. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody
110. Kjeldsen JW, Iversen TZ, Engell- Noerregaard L, Mellemgaard A, Andersen MH, Svane IM. Durable clinical responses and long-term follow-up of stage III-IV non-small-cell lung cancer (NSCLC) patients treated with IDO peptide vaccine in a phase I study - a brief research report. Front Immunol. 2018;9:2145.
2324
haematologica | 2021; 106(9)